In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic respons ...
Health-care companies slid after a profit warning from Eli Lilly. Shares of the obesity-drug maker tumbled after it slashed its projection for fourth-quarter revenue as the market for drugs that ...
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight ... Trump administration. Eli Lilly said Monday it would acquire ...
Eli Lilly and Company (NYSE:LLY) announced on Tuesday that the pharmaceuticals company expects Q4 2024 revenue to be ~$13.5B. The consensus revenue estimate stands at $13.95B. "While the U.S ...
"2024 was a pivotal and highly successful year for Lilly, and we expect to continue ... reimbursement for, and patient access to pharmaceuticals, or reporting obligations related thereto; safety ...